or Try an Advanced Search...

    Technical Analysis for PTGX - Protagonist Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 41.11 0.17% 0.07
    PTGX closed up 0.17 percent on Friday, November 15, 2024, on 1.73 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical PTGX trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    Doji - Bullish? Reversal 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Multiple of Ten Bullish Other 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 0.17%
    Stochastic Reached Oversold Weakness 0.17%
    Below Lower BB Weakness 0.17%
    Older End-of-Day Signals for PTGX ...

       Recent Intraday Alerts

    Alert Time
    Down 3% 2 days ago
    Rose Above Lower Bollinger Band 2 days ago
    Fell Below Previous Day's Low 2 days ago
    Down 2 % 2 days ago
    Down 1% 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PTGX Chart by TradingView
    Basic chart:

    Profile

    Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin

    Is PTGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
    Nov 7 Protagonist GAAP EPS of -$0.54 beats by $0.07, revenue of $4.68M beats by $2.87M
    Nov 7 Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
    Nov 7 Protagonist Therapeutics: Q3 Earnings Snapshot
    Nov 7 Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 5 Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
    Sep 10 Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
    Sep 9 Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years
    Sep 3 Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
    Aug 6 Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
    See more PTGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 48.89
    52 Week Low 16.63
    Average Volume 628,735
    200-Day Moving Average 35.50
    50-Day Moving Average 45.63
    20-Day Moving Average 45.93
    10-Day Moving Average 44.86
    Average True Range 2.01
    RSI (14) 31.51
    ADX 22.71
    +DI 10.90
    -DI 34.31
    Chandelier Exit (Long, 3 ATRs) 42.85
    Chandelier Exit (Short, 3 ATRs) 45.45
    Upper Bollinger Bands 50.19
    Lower Bollinger Band 41.68
    Percent B (%b) -0.07
    BandWidth 18.53
    MACD Line -0.82
    MACD Signal Line -0.03
    MACD Histogram -0.7888
    Fundamentals Value
    Market Cap 2.37 Billion
    Num Shares 57.7 Million
    EPS -2.61
    Price-to-Earnings (P/E) Ratio -15.75
    Price-to-Sales 13.27
    Price-to-Book 5.09
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 44.75
    Resistance 3 (R3) 44.59 43.22 44.15
    Resistance 2 (R2) 43.22 42.29 43.30 43.94
    Resistance 1 (R1) 42.16 41.71 41.47 42.32 43.74
    Pivot Point 40.79 40.79 40.44 40.87 40.79
    Support 1 (S1) 39.73 39.86 39.05 39.90 38.48
    Support 2 (S2) 38.36 39.29 38.44 38.28
    Support 3 (S3) 37.30 38.36 38.07
    Support 4 (S4) 37.47